Biobide is attending several key industry events in April, focusing on advancements in developmental neurotoxicity testing and animal research alternatives. DNT5 – 5th International Conference on Developmental Neurotoxicity Testing (DNT): Our R&D Director and Co-founder, Arantza Muriana, will be participating in the conference at the
The biotechnology group Biat (ticker BST) has presented its results for the year 2023, highlighting a 38% increase in net sales and a positive result for the fiscal year, reaching +1.57 million euros. For detailed information, please refer to the full report here (only in
At the Extraordinary General Meeting of Shareholders held on March 21, 2024, the capitalization of a €2.3 million loan through the issuance of new company shares was approved. The conversion price is €0.4056 per share. This measure will significantly reduce the company’s debt, increase equity,
Join BIAT at the leading European biotech partnering event, Bio-Europe Spring! We’ll be showcasing our cutting-edge solutions in Barcelona (March 18-20) and virtually (March 25-27). What BIAT Offers: Revolutionize your testing: Our New Approach Methods (NAMs) offer efficient and reliable solutions for regulatory and non-regulatory
Discover how the Dose Range Finding (DRF) assay and zebrafish as an alternative model are revolutionizing preclinical research. Learn how DRF determines compound tolerability levels and why zebrafish, with their genetic similarity to humans, transparency, and cost-effectiveness, are invaluable in toxicity screening. Find out how this approach saves time and costs in early drug discovery while ensuring drug safety. Speed up your research with zebrafish and unlock the potential of faster, safer drug development.
Barcelona, Seville (June, 15)– Zip Solutions (Biat Group, ticker BST) and Dr. Miguel Ángel Moreno-Mateos have entered into a strategic collaboration to advance the optimisation of precision gene editing. Gene editing is a revolutionary technology that allows us to make precise changes to DNA, the
